Furthermore, recent studies have highlighted the importance of ESR1 mutations in patients with metastatic ER + BC, which have been shown to have decreased sensitivity to endocrine therapy, thereby requiring higher doses of the relevant drugs9–12. Here, ESR1 is linked to breast cancer.